Skip to main content
Erschienen in: Internal and Emergency Medicine 2/2020

18.06.2019 | IM - ORIGINAL

Defective spleen function in autoimmune gastrointestinal disorders

verfasst von: Paolo Giuffrida, Nicola Aronico, Matteo Rosselli, Marco Vincenzo Lenti, Sara Cococcia, Davide Roccarina, Francesca Saffioti, Mariangela Delliponti, Douglas Thorburn, Emanuela Miceli, Gino Roberto Corazza, Massimo Pinzani, Antonio Di Sabatino

Erschienen in: Internal and Emergency Medicine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Defective spleen function increases susceptibility to bacterial infections which can be prevented by vaccine prophylaxis. Splenic hypofunction can be found in a number of autoimmune disorders; however, no data are available regarding autoimmune atrophic gastritis (AAG), autoimmune enteropathy (AIE) and autoimmune liver disease (AILD). Peripheral blood samples from patients with AAG (n = 40), AIE (n = 3) and AILD (n = 40) were collected. Patients affected by autoimmune disorders already known to be associated with splenic hypofunction, i.e. coeliac disease (CD) and ulcerative colitis (UC), were included as disease controls, while splenectomised patients and healthy subjects were evaluated as positive and negative controls, respectively. Counting of erythrocytes with membrane abnormalities, i.e. pitted red cells, was used as an indicator of spleen function (normal upper limit 4%). Defective splenic function was observed in 22 of the 40 patients with AAG (55.0%), in two of the three patients with AIE (66.6%) and in 35 of the 40 patients with AILD (87.5%). As expected, in untreated CD, refractory CD and UC there was a high prevalence of hyposplenism (43.7%, 88.2% and 54.4%, respectively). Due to the high prevalence of splenic hypofunction, patients with AAG, AILD and AIE should undergo pitted red cell evaluation and, if hyposplenic, they should be candidate to vaccine prophylaxis against encapsulated bacteria.
Literatur
1.
Zurück zum Zitat Di Sabatino A, Carsetti R, Corazza GR (2011) Post-splenectomy and hyposplenic states. Lancet 378:86–97CrossRef Di Sabatino A, Carsetti R, Corazza GR (2011) Post-splenectomy and hyposplenic states. Lancet 378:86–97CrossRef
2.
Zurück zum Zitat Corazza GR, Zoli G, Di Sabatino A et al (1999) A reassessment of splenic hypofunction in celiac disease. Am J Gastroenterol 94:391–397CrossRef Corazza GR, Zoli G, Di Sabatino A et al (1999) A reassessment of splenic hypofunction in celiac disease. Am J Gastroenterol 94:391–397CrossRef
3.
Zurück zum Zitat Di Sabatino A, Brunetti L, Carnevale Maffè G et al (2013) Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 19:2313–2318CrossRef Di Sabatino A, Brunetti L, Carnevale Maffè G et al (2013) Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 19:2313–2318CrossRef
4.
Zurück zum Zitat Di Sabatino A, Rosado MM, Ciccocioppo R et al (2005) Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. Am J Gastroenterol 100:1788–1795CrossRef Di Sabatino A, Rosado MM, Ciccocioppo R et al (2005) Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. Am J Gastroenterol 100:1788–1795CrossRef
5.
Zurück zum Zitat Di Sabatino A, Aronico N, Giuffrida P et al (2018) Association between defective spleen function and primary eosinophilic gastrointestinal disorders. J Allergy Clin Immunol Pract 6:1056–1058CrossRef Di Sabatino A, Aronico N, Giuffrida P et al (2018) Association between defective spleen function and primary eosinophilic gastrointestinal disorders. J Allergy Clin Immunol Pract 6:1056–1058CrossRef
6.
Zurück zum Zitat Di Sabatino A, Rosado MM, Cazzola P et al (2006) Splenic hypofunction and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol 4:179–186CrossRef Di Sabatino A, Rosado MM, Cazzola P et al (2006) Splenic hypofunction and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol 4:179–186CrossRef
7.
Zurück zum Zitat Simons M, Scott-Sheldon LAJ, Risech-Neyman Y et al (2018) Celiac disease and increased risk of pneumococcal infection: a systematic review and meta-analysis. Am J Med 131:83–89CrossRef Simons M, Scott-Sheldon LAJ, Risech-Neyman Y et al (2018) Celiac disease and increased risk of pneumococcal infection: a systematic review and meta-analysis. Am J Med 131:83–89CrossRef
8.
Zurück zum Zitat Emilsson L, Lebwohl B, Green PH et al (2018) Mucosal healing and the risk of serious infections in patients with celiac disease. United Eur Gastroenterol J 6:55–62CrossRef Emilsson L, Lebwohl B, Green PH et al (2018) Mucosal healing and the risk of serious infections in patients with celiac disease. United Eur Gastroenterol J 6:55–62CrossRef
9.
Zurück zum Zitat Kruetzmann S, Rosado MM, Weber H et al (2003) Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 197:939–945CrossRef Kruetzmann S, Rosado MM, Weber H et al (2003) Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 197:939–945CrossRef
10.
Zurück zum Zitat Di Sabatino A, Rosado MM, Cazzola P et al (2008) Splenic function and IgM-memory B cells in Crohn’s disease patients treated with infliximab. Inflamm Bowel Dis 14:591–596CrossRef Di Sabatino A, Rosado MM, Cazzola P et al (2008) Splenic function and IgM-memory B cells in Crohn’s disease patients treated with infliximab. Inflamm Bowel Dis 14:591–596CrossRef
11.
Zurück zum Zitat Dixon MF, Genta RM, Yardley JH et al (1996) Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181CrossRef Dixon MF, Genta RM, Yardley JH et al (1996) Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181CrossRef
12.
Zurück zum Zitat Di Sabatino A, Biagi F, Lenzi M et al (2017) Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases. Dig Liver Dis 49:947–956CrossRef Di Sabatino A, Biagi F, Lenzi M et al (2017) Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases. Dig Liver Dis 49:947–956CrossRef
13.
Zurück zum Zitat European Association for the Study of the Liver (2015) EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol 63:971–1004CrossRef European Association for the Study of the Liver (2015) EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol 63:971–1004CrossRef
14.
Zurück zum Zitat European Association for the Study of the Liver (2017) EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67:145–172CrossRef European Association for the Study of the Liver (2017) EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67:145–172CrossRef
15.
Zurück zum Zitat European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51:237–267CrossRef European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51:237–267CrossRef
16.
Zurück zum Zitat Di Sabatino A, Corazza GR (2009) Coeliac disease. Lancet 373:1480–1493CrossRef Di Sabatino A, Corazza GR (2009) Coeliac disease. Lancet 373:1480–1493CrossRef
17.
Zurück zum Zitat Rubio-Tapia A, Murray JA (2010) Classification and management of refractory coeliac disease. Gut 59:547–557CrossRef Rubio-Tapia A, Murray JA (2010) Classification and management of refractory coeliac disease. Gut 59:547–557CrossRef
18.
Zurück zum Zitat Magro F, Gionchetti P, Eliakim R et al (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 11:649–670CrossRef Magro F, Gionchetti P, Eliakim R et al (2017) Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 11:649–670CrossRef
19.
Zurück zum Zitat Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82–86CrossRef Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82–86CrossRef
20.
Zurück zum Zitat Markus HS, Muller AF, Toghill PJ (1993) Splenic function, assessed by quantification of erythrocyte membrane pits, is normal in chronic active hepatitis and primary biliary cirrhosis. J Hepatol 18:106–111CrossRef Markus HS, Muller AF, Toghill PJ (1993) Splenic function, assessed by quantification of erythrocyte membrane pits, is normal in chronic active hepatitis and primary biliary cirrhosis. J Hepatol 18:106–111CrossRef
21.
Zurück zum Zitat Trevisani F, Castelli E, Foschi FG et al (2002) Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome. Gut 50:707–712CrossRef Trevisani F, Castelli E, Foschi FG et al (2002) Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome. Gut 50:707–712CrossRef
22.
Zurück zum Zitat Carsetti R, Rosado MM, Wardemann H (2004) Peripheral development of B cells in mouse and man. Immunol Rev 197:179–191CrossRef Carsetti R, Rosado MM, Wardemann H (2004) Peripheral development of B cells in mouse and man. Immunol Rev 197:179–191CrossRef
23.
Zurück zum Zitat Arnott A, Jones P, Franklin LJ et al (2018) A registry for patients with asplenia/hyposplenism reduces the risk of infections with encapsulated organisms. Clin Infect Dis 67:557–561CrossRef Arnott A, Jones P, Franklin LJ et al (2018) A registry for patients with asplenia/hyposplenism reduces the risk of infections with encapsulated organisms. Clin Infect Dis 67:557–561CrossRef
24.
Zurück zum Zitat Di Sabatino A, Lenti MV, Corazza GR (2018) Spleen registry: still a chimera. Clin Infect Dis 67:562–563CrossRef Di Sabatino A, Lenti MV, Corazza GR (2018) Spleen registry: still a chimera. Clin Infect Dis 67:562–563CrossRef
Metadaten
Titel
Defective spleen function in autoimmune gastrointestinal disorders
verfasst von
Paolo Giuffrida
Nicola Aronico
Matteo Rosselli
Marco Vincenzo Lenti
Sara Cococcia
Davide Roccarina
Francesca Saffioti
Mariangela Delliponti
Douglas Thorburn
Emanuela Miceli
Gino Roberto Corazza
Massimo Pinzani
Antonio Di Sabatino
Publikationsdatum
18.06.2019
Verlag
Springer International Publishing
Erschienen in
Internal and Emergency Medicine / Ausgabe 2/2020
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-019-02129-w

Weitere Artikel der Ausgabe 2/2020

Internal and Emergency Medicine 2/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.